CLINICAL EXPERIENCE OF KW-1070 (FORTIMICIN) IN URINARY TRACT INFECTIONS
KW-1070 (fortimicin), a new aminoglycoside antibiotic, was intramuscularly injected at the dose of 400mg or 600mg per day for 5 days to 55 patients hospitalized in the department of urology at Kyushu University Hospital and 10 relevant hospitals. The clinical effect was excellent in one case with ac...
Saved in:
| Published in | CHEMOTHERAPY Vol. 29; no. Supplement2; pp. 616 - 630 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English Japanese |
| Published |
Japanese Society of Chemotherapy
1981
|
| Online Access | Get full text |
Cover
Loading…
| Summary: | KW-1070 (fortimicin), a new aminoglycoside antibiotic, was intramuscularly injected at the dose of 400mg or 600mg per day for 5 days to 55 patients hospitalized in the department of urology at Kyushu University Hospital and 10 relevant hospitals. The clinical effect was excellent in one case with acute simple pyelonephritis. The effect against chronic complicated urinary tract infections was excellent in 8, good in 22, poor in 16 and unassessable in 8 cases. The overall clinical effectiveness rate was 65.2%; 58.3% among 36 patients given 600mg of fortimicin per day and 90% among 10 patients given 600 mg of KW-1070 per day. Bacteriologically, 47 out of 63 strains isolated from patients disappeared after treatment. The drug was found to be effective against urinary tract infections due to S. marcescens, E. coli, C. freundii and S. faecalis, but not effective against those due to P. aeruginosa. Side effects of the drug were encountered in 2 cases ; pain at the injected area and elevation of BUN. |
|---|---|
| ISSN: | 0009-3165 1884-5894 |
| DOI: | 10.11250/chemotherapy1953.29.Supplement2_616 |